10 Year Follow-up of CALGB 10603/RATIFY: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
- Citation:
- Blood vol 144 (Supplement 1) 218
- Meeting Instance:
- ASH 2024
- Year:
- 2024
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Long-Term-Followup
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- Novartis
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Richard Stone Jun Yin Ilene Galinsky Richard A. Larson Hartmut Dohner Axel Benner Maral Saadati Sumithra J. Mandrekar Ben L. Sanford Susan M. Geyer Thomas Prior Rebecca B. Klisovic Hubert Serve Sergio Amadori Bruno Medeiros Richard F. Schlenk Andrew H. Wei Christian Thiede Konstanze Döhner Guido Marcucci Jorge Sierra Miguel A. Sanz Joseph Brandwein Theo J.M. de Witte Frederick R. Appelbaum Martin S. Tallman Jürgen Krauter Arnold Ganser Gerhard Ehninger Dietger W. Niederwieser
- Networks:
- CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-OH007
- Study
- CALGB-10603
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: